乳腺癌患者淋巴显像中前哨淋巴结未显影的危险因素
该单中心回顾性研究纳入2011年3月至2021年4月1886例前哨淋巴结淋巴显像操作,注射后4小时未显影率为25.1%,再次注射后降至9.4%;多因素分析显示年龄≥70岁、BMI≥30 kg/m2及不可触及肿瘤是前哨淋巴结未显影的独立预测因素,而肿瘤位置、放射性药物品牌、注射剂量与体积及操作者经验与未显影无关。
要点
- 年龄≥70岁、BMI≥30 kg/m2及不可触及肿瘤是前哨淋巴结淋巴显像未显影的独立危险因素。
- 注射后4小时未显影率为25.1%,再次注射后降至9.4%。
- 肿瘤位置、放射性药物品牌、注射剂量与体积及操作者经验与未显影无关。
核心结论
- 乳腺癌患者术前淋巴显像中前哨淋巴结未显影的危险因素为年龄≥70岁、BMI≥30 kg/m2和不可触及肿瘤。
研究设计与样本
- 单中心回顾性研究,收集并回顾阿姆斯特丹UMC数据库2011年3月至2021年4月所有前哨淋巴结淋巴显像操作数据,共纳入1886例操作。
主要发现
- 注射后4小时淋巴显像前哨淋巴结未显影率为25.1%,再次注射后未显影率降至9.4%。
- 多因素分析显示年龄≥70岁(P<0.001;OR:2.27;95%CI:1.46-3.53)是前哨淋巴结未显影的独立预测因素。
- 多因素分析显示BMI≥30 kg/m2(P=0.031;OR:1.48;95%CI:1.04-2.12)是前哨淋巴结未显影的独立预测因素。
- 多因素分析显示不可触及肿瘤(P=0.004;OR:1.54;95%CI:1.15-2.07)是前哨淋巴结未显影的独立预测因素。
- 肿瘤位置、放射性药物品牌、注射剂量与体积、配制者及注射者经验与前哨淋巴结未显影无关;再次注射后患者、肿瘤或示踪剂特征均与未显影无关。
临床怎么用
- 对于年龄≥70岁、BMI≥30 kg/m2或不可触及肿瘤的乳腺癌患者,应预期前哨淋巴结淋巴显像未显影风险较高,可考虑再次注射以提高显影率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN in some patients. The purpose of this retrospective study was to identify risk factors associated with SLN nonvisualization on lymphoscintigraphy. For this single-center retrospective study, all data of lymphoscintigraphy of SLN procedures from March 2011 to April 2021 were collected and reviewed from the Amsterdam UMC database. RESULTS: A total of 1886 SLN procedures were included in this study. The SLN nonvisualization rate was 25.1% on lymphoscintigraphy at 4 h post-injection. The SLN nonvisualization rate decreased to 9.4% after reinjection. Multivariable analysis showed that age ≥ 70 years (P < 0.001; OR: 2.27; 95% CI: 1.46-3.53), BMI ≥ 30 kg/m2 (P = 0.031; OR: 1.48; 95% CI: 1.04-2.12) and nonpalpable tumors (P = 0.004; OR: 1.54; 95% CI: 1.15-2.07) were independent predictors of SLN nonvisualization. Tumor location, brand of radiopharmaceutical, injected dose and volume, experience of preparer and administrator were not associated with SLN nonvisualization. None of the patient, tumor or tracer characteristics were associated with SLN nonvisualization after radiotracer reinjection. CONCLUSIONS: This study shows that risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy are age ≥ 70 years, BMI ≥ 30 kg/m2 and nonpalpable tumors. Our results support the notion that SLN lymphoscintigraphy is a very robust technique that does not depend on the experience of the preparer or administrator of the radiotracer.
引用
- Chahid Y, Qiu X, van de Garde EMW, et al. Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients. EJNMMI Res. 2021. PMID: 34106341. doi:10.1186/s13550-021-00793-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。